(Q36877861)

16 August 2017

1 reference

title

Engineering antibodies for imaging and therapy (English)

1 reference

16 August 2017

Carter P

1

1 reference

16 August 2017

Merchant AM

series ordinal

2

1 reference

16 August 2017

publication date

1 August 1997

1 reference

Current Opinion in Biotechnology

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

449-454

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

16 August 2017

1 reference

7 January 2021

Making antibodies by phage display technology

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Mice perform a human repertoire

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Recent developments in immunotoxin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Engineering bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Toward the production of bispecific antibody fragments for clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Immunoadhesins as research tools and therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Monoclonal antibody-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Antibody-enzyme conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Isolation of high affinity human antibodies directly from large synthetic repertoires.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Humanization of immunotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

1 reference

7 January 2021

Development of anti-p185HER2 immunoliposomes for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

High level Escherichia coli expression and production of a bivalent humanized antibody fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Brain drug delivery of small molecules using immunoliposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

High level secretion of a humanized bispecific diabody from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Remodeling domain interfaces to enhance heterodimer formation

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Phage diabody repertoires for selection of large numbers of bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Hybrid hybridomas and their use in immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Bispecific monoclonal antibodies from hybrid hybridomas

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [gamma-32P]-ATP.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Redefining the minimal antigen-binding fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Naturally occurring antibodies devoid of light chains

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Antibody VH domains as small recognition units

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2897%2980067-5

7 January 2021

10.1016/S0958-1669(97)80067-5

Identifiers

DOI

1 reference

16 August 2017

1 reference